Nuevolution Announces Formation of Strong Scientific Advisory Panel
News Mar 14, 2013
Nuevolution teams with key scientific advisors to assist the progression of its internal drug discovery programs within Inflammation and Oncology.
In June 2012, Nuevolution has announced the closing of a new financing round, and the plans to initiate internal drug discovery efforts.
Since then, Nuevolution has prioritized more than 30 high-value challenging targets for screening, which has been initiated.
The target prioritization and further program decisions have been made in close collaboration with the newly appointed advisors.
Professor Sir Marc Feldmann, Kennedy Institute, UK. Dr. Feldmann is a world-renowned scientist within immunology and a special interest in the fields of autoimmune diseases and the roles of cytokines.
He is recipient of numerous honors and awards over the years and has pioneered the work on the development of antibodies against TNFα for the treatment of RA.
Professor Dr. Gordon B. Mills, MD Anderson Cancer Center, US. Dr. Mills is a world-leading scientist within oncology and professor and chair in the Department of Systems Biology in the Division of Cancer Medicine at the MD Anderson Cancer Center, where he holds the Olga Keith Wiess Distinguished University Chair in Cancer Medicine.
Dr. Mills is co-director of the Sheikh Khalifa bin Zayed Al Nahyan Institute for Personalized Cancer Therapy and director Kleberg Center for Molecular Markers.
He also serves as advisor for pre-clinical and clinical oncology studies supporting numerous pharmaceutical- and biotechnology companies.
Dr. Alan Collis, formerly Novartis and Aventis, US. Dr. Collis has 25 years of industry experience. He has a very strong track-record within chemistry, DMPK studies and pre-clinical candidate development.
He has served as head of section within oncology at Novartis and as a central member of their Oncology and Exploratory Chemistry leadership team.
At Aventis he served at their Review Board involved with recommendations from target selection through to phase IIb initiation within inflammation and CNS diseases.
“We are obviously delighted to receive support from such a strong and experienced advisory team to help us leverage our Chemetics® technology platform and plan and promote our own pipeline” said Thomas Franch, CSO of Nuevolution.
Franch continued, “We look forward to working with Marc, Gordon and Alan and we are confident that they will help accelerate our discovery projects and provide substantial value to our programs.
Disease-Fighting 'Warheads' Hidden in BacteriaNews
Bacteria found in soil may harbor a potential game-changer for drug design. A new study by Scripps Research, published today in Nature Communications, suggests scientists could build better drugs by learning from bacteria-derived molecules called thiocarboxylic acids.READ MORE
Exploring Challenges in the Synthesis of Pharmaceutical DrugsNews
This summer, Wendell and Loretta Hess Professor of Chemistry Ram Mohan will travel to India and Hong Kong to deliver a series of post-graduate workshops on advanced concepts in organic synthesis.
His workshop “Advanced Concepts in the Synthesis of Pharmaceutical Drugs” at the Indian Institute of Technology Indore will explore the unique, real-world challenges in the pharmaceutical industry to synthesize drugs that are both commercially viable and eco-friendly.
Modern Alchemists are Making Chemistry GreenerNews
Ancient alchemists tried to turn lead and other common metals into gold and platinum. Modern chemists in Paul Chirik’s lab at Princeton are transforming reactions that have depended on environmentally unfriendly precious metals, finding cheaper and greener alternatives to replace platinum, rhodium and other precious metals in drug production and other reactions.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018